Brief: Adverum Biotechnologies Inc Reports Quarterly Loss Per Share Of $0.33
30/03/2023 21:14
March 30 (Reuters) - Adverum Biotechnologies Inc
ADVM.O :
* ADVERUM BIOTECHNOLOGIES REPORTS FOURTH QUARTER AND FULL
YEAR
2022 FINANCIAL RESULTS AND PROVIDES PHASE 2 LUNA TRIAL UPDATE
* ADVERUM BIOTECHNOLOGIES INC - CASH RUNWAY INTO 2025
* ADVERUM BIOTECHNOLOGIES INC- QTRLY LOSS PER SHARE $0.33
Source text for Eikon: ID:nGNX1y8yKQ
Further company coverage: ADVM.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Adverum Biotechnologies
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Brief: Adverum Reminds Stockholders To Tender Their Shares Into The Offer By Lilly
Brief: Adverum Biotechnologies Inc - Are-Nc Region No. 21 Llc Terminates Certain Lease Agreement With Adverum Biotechnologies - SEC Filing
Eli Lilly bets on eye care with buyout of gene therapy developer Adverum (updated)